Genetic Events That Limit the Efficacy of MEK and RTK Inhibitor Therapies in a Mouse Model of KRAS-Driven Pancreatic Cancer

Piergiorgio Pettazzoni1,2, Andrea Viale1,2, Parantu Shah3, Alessandro Carugo1,2, Haoqiang Ying1, Huamin Wang5, Giannicola Genovese2, Sahil Seth3, Rosalba Minelli6, Tessa Green1,2, Emmet Huang-Hobbs1,2, Denise Corti1,2, Nora Sanchez1,2, Luigi Nezli2, Matteo Marchesini1,2, Avnish Kapoor4, Wantong Yao1,2, Maria E. Di Francesco3, Alessia Petrocchi3, Angela K. Deem1,2, Kenneth Scott6, Simona Colla4, Gordon B. Mills7, Jason B. Fleming8, Timothy P. Heffernan3, Philip Jones3, Carlo Toniatti3, Ronald A. DePinho4, and Giulio F. Draetta1,2,3

Abstract

Mutated KRAS (KRAS*) is a fundamental driver in the majority of pancreatic ductal adenocarcinomas (PDAC). Using an inducible mouse model of KRAS*-driven PDAC, we compared KRAS* genetic extinction with pharmacologic inhibition of MEK1 in tumor spheres and in vivo. KRAS* ablation blocked proliferation and induced apoptosis, whereas MEK1 inhibition exerted cytostatic effects. Proteomic analysis evidenced that MEK1 inhibition was accompanied by a sustained activation of the PI3K–AKT–MTOR pathway and by the activation of AXL, PDGFRα, and HER1–2 receptor tyrosine kinases (RTK) expressed in a large proportion of human PDAC samples analyzed. Although single inhibition of each RTK alone or plus MEK1 inhibitors was ineffective, a combination of inhibitors targeting all three coactivated RTKs and MEK1 was needed to inhibit proliferation and induce apoptosis in both mouse and human low-passage PDAC cultures. Importantly, constitutive AKT activation, which may mimic the fraction of AKT2-amplified PDAC, was able to bypass the induction of apoptosis caused by KRAS* ablation, highlighting a potential inherent resistance mechanism that may inform the clinical application of MEK inhibitor therapy. This study suggests that combinatorial-targeted therapies for pancreatic cancer must be informed by the activation state of each putative driver in a given treatment context. In addition, our work may offer explanatory and predictive power in understanding why inhibitors of EGFR signaling fail in PDAC treatment and how drug resistance mechanisms may arise in strategies to directly target KRAS.

Introduction

Pancreatic ductal adenocarcinoma (PDAC) is among the deadliest tumors, and fewer than 5% of newly diagnosed patients survive more than 5 years (1). Only a small fraction of cases present with local disease and are eligible for potentially curative surgical resection; whereas, the remaining patients possess locally advanced or metastatic disease and receive systemic and palliative therapies. The treatment of locally advanced or metastatic PDAC with gemcitabine and radiation provides modest survival benefit, and recent clinical trials show further marginal improvement with combination of 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) or with nab-paclitaxel (2,3).

Oncogenic mutation of KRAS is a signature molecular event in PDAC and functions as a key driver of disease initiation and maintenance in approximately 90% of cases (4). Targeting oncogenic KRAS represents an ideal therapeutic strategy, although attempts to target KRAS directly have thus far failed, whereas farnesyltransferase inhibitors have shown no clinical benefit (5). Indeed targeting KRAS (or other structurally related family members) remains one of the biggest challenges in oncology (5) and has inspired a large scale NCI-directed effort (6,7). Inhibition of KRAS downstream effectors might in principle achieve similar results, and attempts have been made to target the MAPK signaling cascade and the PI3K–AKT–MTOR signaling pathway in multiple cancer subtypes. Combinatorial inhibition of these two critical effector pathways has resulted in favorable therapeutic outcomes in multiple preclinical studies in mutant RAS-driven tumor...
models (8,9); however, recent clinical data showed that these combination therapies are associated with toxicities that might ultimately limit the feasibility of this approach (10). A multitude of alternative targeted therapy regimens have been clinically tested for the treatment of PDAC and, apart from the statistically significant albeit minimal effects seen with EGFR inhibitors, none has provided a clear clinical benefit (11). Moreover, despite the frequent overexpression of EGFR in KRAS-driven PDAC and the essentiality of EGFR for tumor establishment (12), the therapeutic benefits of EGFR inhibition alone or in combination with gemcitabine remain very modest (13).

Here, we use a conditional genetically engineered mouse model (GEMM) of PDAC engineered with pancreas-specific inducible mutant KRAS (KRASG12DGEMM) allele to evaluate signaling pathway patterns emerging with either genetic abrogation of KRASG12D or pharmacologic inhibition of MEK1 in vivo or in vitro. As 2D-cultured cancer cell lines are poorly predictive of in vivo responses to pharmacologic inhibition (14), we use a 3D culture system of primary tumor-derived spheres as well as in vivo tumor testing. We show that MEK1 inhibition activates a network of receptor tyrosine kinases (RTK) that may limit the efficacy of single anti–RTK-based therapies alone or in combination with MEK1 inhibitors. Furthermore, activation of AXL, which is highly expressed in our inducible KRASG12DGEMM as well as in a significant number of clinical PDAC samples, might limit the benefits of MEK1–EGFR inhibitor combination treatments currently undergoing clinical testing.

Materials and Methods

Cell culture

iKRAS cells were derived from P48 CRE_TetO-LSL-KRAS G12D_Rosa-rtTA_p53f/f, tumor-bearing mice (15). Tumors were minced and digested in collagenase IV and dispase (4 mg/mL) for 1 hour at 37°C on an orbital shaker and subsequently filtered through a 40 μm nylon cell strainer. For conventional tissue culture, cells were maintained in RPMI-1640 supplemented with 10% FBS, 2 mmol/L glutamine, and 1% penicillin/streptomycin. For 3D tissue culture, cells were maintained in low-attachment plates in stem cell medium (MEBM; Lonza) supplemented with 2 mmol/L glutamine (Invitrogen), B27 (Invitrogen), 20 ng/mL hEGF (PeproTech), and 20 ng/mL hFGF (PeproTech). 5 μg/mL b-Insulin (Roche), 0.5 μmol/L hydrocortisone (Sigma-Aldrich), 100 μmol/L β-mercaptoethanol (Sigma-Aldrich), 4 μg/mL heparin (Sigma-Aldrich). Methocult M3134 (STEMCELL Technologies) was added to stem cell medium (final concentration 0.8%) to keep tumor cells growing as clonal spheres (16). MIA PaCa-2 and Panc1 cells were obtained from the ATCC.

Cell viability

To determine viability of cells grown in 3D conditions, cells embedded in methylcellulose-based semisolid media were exposed to 1 μmol/L calcein (Life Technologies), incubated for 30 minutes, and quantified through ImageXpress velos (Molecular Devices) apparatus. Alternatively, cells were collected through centrifugation, trypsinized, stained in 1X Annexin V buffer with Annexin V–phycoerythrin and 7AAD (BD Biosciences) for 5 minutes at room temperature and analyzed by flow cytometry.

Animal studies

Animal studies were conducted according to IACUC guidelines. For allograft and xenograft establishment, 5 × 10^6 iKRAS cells or 2 × 10^6 PATC cells were suspended in 200 μL of 50% HBSS, 50% growth factor reduced Matrigel and injected s.c. in the right flank of nude mice. Tumor volume was assessed using caliper measurements and calculated according to the standard formula: length/2 × width^2. AZD6244, BEZ235, laptatib, and imatinib were administered through oral gavage, whereas AXLI was administered by i.p. injection. The drugs were dissolved in the following vehicles: (i) AZD6244 and laptatinib, 10% methylcellulose, 2% tween 20; (ii) BEZ235, 50% 2 methylproprilone, 50% PEG300; (iii) imatinib, sterile PBS; and (iv) AXLI, 10% DMSO, 90% PEG300.

Reverse phase protein array

The reverse phase protein array (RPPA) protein expression profiles were generated by the MD Anderson RPPA core facility following standard protocols (17). More information can be found at http://www.mdanderson.org/education-and-research/resources-for-professionals/scientific-resources/core-facilities-and-services/functional-proteomics-rppa-core/index.html. The RPPA dilution curves were fitted with a logistic model from the SuperCurve R-package (18,19), and RPPA data were normalized by protein loading. Normalized log2-transformed data were used for further statistical analyses. Differential expression between two conditions was calculated using the Student t test and multiple conditions with one-way ANOVA with custom R-scripts. Raw P values were corrected for multiple hypothesis testing using the Benjamini–Hochberg correction (FDR), and protein changes were considered significant when FDR was less than 10%.

Western blot analysis

Whole-cell extracts were electrophoresed by SDS-PAGE and transferred to a nitrocellulose membrane using a semi-dry transfer apparatus according to the manufacturer’s instructions (Bio-Rad). After incubation with 5% nonfat milk in TBST (10 mmol/L Tris, pH 8.0, 150 mmol/L NaCl, 0.5% Tween 20) for 60 minutes, the membranes were incubated with primary antibodies (see Supplementary Material for detailed antibodies list) at 4°C overnight. Membranes were washed three times for 10 minutes and incubated with a 1:5,000 dilution of horseradish peroxidase (HRP)–conjugated secondary antibodies. Blots were washed with TBST three times and developed after ECL-based chemiluminescence reaction through film exposure.

Immunohistochemistry

Formalin-fixed tumors were dehydrated and paraffin-embedded according to standard procedures. Slices (5 μm) were cut using a microtome, rehydrated, and subjected to antigen unmasking by heating at 95°C for 30 minutes with a commercially available antigen unmasking solution (Citra Plus—Biogenex). Slices were subsequently incubated with 3% hydrogen peroxide for 15 minutes, incubated with primary antibodies, washed, incubated with HRP-conjugated secondary antibodies, washed, and developed through DAB incubation. Slices were counterstained with hematoxylin, dehydrated, and mounted.

Real-time PCR

cDNAs were synthesized from RNA through reverse transcription with a commercially available kit following the manufacturer’s instructions (Invitrogen). Real-time PCR was performed by a TaqMAN-based reaction by using the following sets of Invitrogen primers and probes: growth arrest–specific 6 (GAS6: mmol/L 00490378_m1), PDGFA (mmol/L 01205760_m1), PDGFB...
KRASG12D, we derived tumor cell lines from our previously characterized GEMM model harboring an inducible KRASG12D allele (P48 CRE_TetO-LSL-KRASG12D_Rosa-rtTA_p53). To evaluate changes in cell signaling upon genetic ablation of KRASG12D, we first assessed the impact of MAPK and PI3K/AKT/MTOR signaling in our iKRAS model. As KRASG12D is undruggable, significant effort has focused on dampening its signaling cascade. To determine which pharmacologic treatment(s) most closely recapitulate the signaling events and the phenotypic consequences of KRASG12D ablation observed in our iKRAS model, we treated iKRAS cells kept in the presence of doxycycline with the MEK1 inhibitor AZD6244 at a dose (2 μmol/L) capable of inhibiting ERK phosphorylation to an extent comparable with that observed upon 48 hours of doxycycline withdrawal (Fig. 1A). Although AZD6244 treatment significantly inhibited cell proliferation, there was a notable lack of cell death (Fig. 1C and D). To conduct parallel in vivo studies, mice carrying iKRAS-derived subcutaneous allograft were divided into three groups: continued doxycycline administration, doxycycline withdrawal, or continued doxycycline administration plus AZD6244 at 100 mg/kg/d, a dose that achieves the highest pharmacologic pathway repression. Similar to the 3D model, we observed complete tumor regression upon doxycycline withdrawal, but only blunted tumor growth with AZD6244 treatment (Fig. 1E). Correspondingly, immunohistochemical analysis of tumors following doxycycline withdrawal confirmed robust inhibition of cell proliferation (Ki67) and induction of apoptosis (cleaved caspase-3) compared with reduced cell proliferation and no apoptosis with AZD6244 treatment. Of note, inhibition of ERK phosphorylation was similar in AZD6244-treated and KRAS-ablated tumors (Fig. 1F).

**KRASG12D ablation results in coextinction of MAPK and PI3K–AKT–MTOR signaling, whereas MEK inhibition results in extinction of MAPK signaling with concomitant activation of AKT**

We next studied signaling pathways to potentially identify differentially regulated signaling events that may underlie the distinct biologic phenotypes of KRASG12D extinction versus MEK inhibition. To that end, we performed an RPPA analysis of lysates derived from three independent iKRAS lines cultured in the presence of doxycycline, after doxycycline withdrawal, or doxycycline plus AZD6244 treatment (2 μmol/L). The heatmap (Fig. 2A) reveals that multiple effectors of the PI3K–AKT–MTOR signaling pathway showed differential regulation in the setting of KRASG12D extinction versus MEK inhibition. Specifically, KRASG12D extinction showed dramatic repression of PI3K–AKT–MTOR targets: phospho-PRAS40, phospho-GSK alpha/beta, and phospho MTOR relative to KRASG12D–expressing cells, whereas MEK inhibition resulted in a partial attenuation of these signaling components. Conversely, KRASG12D ablation or MEK inhibitor treatment induced robust and minor accumulations of FOXO3a, respectively. Notably, ERK phosphorylation on Thr202 and Tyr204 and RAS–MAPK-regulated phosphorylation of ribosomal protein S6 on Ser235 and Ser236 (20) were similarly inhibited by KRASG12D ablation or MEK inhibitor treatment. Immunohistochemistry analysis confirmed comparable signaling changes in treated tumors (Fig. 2B). Moreover, Western blot analysis of iKRAS cells cultured with doxycycline, after doxycycline withdrawal, or doxycycline plus AZD6244 treatment (2 μmol/L) evidenced a robust increment in phospho-AKT at Thr308 and Ser473 in AZD6244-treated samples whereas KRASG12D ablation caused a time-dependent reduction of phospho AKT levels (Fig. 2C).

To assess whether the differential PI3K–AKT–MTOR activation status observed upon KRASG12D ablation versus MEK inhibition may be responsible for the different tumor response, we established iKRAS-derived allografts and treated them with AZD6244 (100 mg/kg/d) and/or BEZ235 (40 mg/kg/d; a dual PI3K–MTOR inhibitor). Inhibition of the MAPK signaling arm or PI3K–AKT–MTOR arms alone provided minimal antitumor benefit, whereas concurrent inhibition of both effector pathways exerted robust antitumor efficacy mimicking the phenotypic changes observed upon KRASG12D ablation (Fig. 2D).

**Both KRASG12D ablation and MEK inhibition activate EGFR, HER2, PDGFRα, and AXL.**

It has been shown that MEK inhibition results in hyperactivation of the erythroblast leukemia viral oncogene homolog (ERBB) RTKs (21), which could explain the increase in AKT phosphorylation observed upon MEK1 inhibitor treatment. Phospho-RTK analyses performed on resected iKRAS-derived tumors showed detectable basal levels of phosphorylated platelet-derived growth factor receptor alpha (PDGFRα)
in KRAS<sup>G12D</sup>-expressing tumors, as well as a robust increase in phosphorylation of EGFR, human epidermal growth factor receptor 2 (HER2), and P-AXL upon either AZD6244 treatment or doxycycline withdrawal (Fig. 3A). To determine whether increased RTK activation resulted from increased expression of the RTKs or their ligands, we analyzed protein lysates and cDNA from iKRAS cells. We found that RTK activation was the result of both, as KRAS ablation increased expression of PDGFRα and AXL, as well as the PDGFR ligands PDGFα, PDGFβ, PDGFc, and the AXL ligand GAS6 (Fig. 3B and C and Supplementary Fig. S4). In contrast, none of the EGFR family ligands assessed showed an increased expression (data not shown).

Diverse mechanisms may be responsible for the RTK activation observed in response to MEK inhibition. In particular, it has been shown that AZD6244 treatment inhibits an MAPK-mediated phosphorylation of EGFR and HER2 that prevents receptor dimerization and activation (21), whereas a more broad transcriptional RTK activation occurs due to inhibition of c-myc (22). Because AXL levels were elevated upon KRAS<sup>G12D</sup> ablation, we postulated that c-myc may negatively regulate AXL expression. As expected, both ablation of KRAS<sup>G12D</sup> and MEK inhibitor treatment repressed c-myc expression, and knockdown of c-myc in iKRAS lines resulted in increased AXL expression (Fig. 3D and E).
RTKs drive redundant signaling to the PI3K–AKT–MTOR pathway

To assess the effect on signaling modulation of each RTK activated upon MEK inhibition, we performed RPPA analysis on iKRAS cells exposed to single RTK inhibitors as well as their different combinations with or without AZD6244 treatment. To inhibit each RTK, we used the dual EGFR–HER2 inhibitor lapatinib, the PDGFRα inhibitor imatinib, and the novel AXL inhibitor CH5451098 (hereafter referred to as AXLi; ref. 23). AXLi showed superior selectivity and potency over other available AXL inhibitors, and we extensively evaluated its in vivo safety and pharmacokinetics (Supplementary Figs. S6, S7, and S8). RPPA profiles (Fig. 4A) from single or combined RTK inhibitor–treated iKRAS cells showed no significant impact on protein or phosphoprotein abundance of members of the PI3K–AKT–MTOR signaling pathway compared with untreated controls. This is consistent with our observations that in basal, untreated conditions, iKRAS cells show minimal RTK activation and support the view that the inhibitors used in the present study are “on target” and are delivered at appropriate doses to extinguish MEK inhibitor–mediated RTK activation (Supplementary Fig. S9). Moreover, no off-pathway effects were detected in cells lacking RTK activation. In contrast, combined treatment with RTK inhibitors and AZD6244 showed a significant impact on proteins and phosphoproteins of the PI3K–AKT–MTOR signaling pathway only when AZD6244 was combined with all three RTK inhibitors, which produced pathway inhibition analogous to that observed upon KRASG12D ablation.

To confirm our results in vivo, we evaluated the levels of phospho-S6 kinase as a marker of the activity of the PI3K–AKT–MTOR pathway in tumors treated with AXLi (30 mg/kg/d), imatinib (100 mg/kg/d), or lapatinib (100 mg/kg/d) alone or in combination with AZD6244 (100 mg/kg/d) for 5 days. Consistent with the RPPA data, neither treatment with a single RTK inhibitor nor with combined single RTK and MEK inhibitors affected P-S6 levels (Fig. 4B), thus confirming our earlier conclusion that diverse RTKs drive redundant inputs to the PI3K–AKT–MTOR signaling pathway. Ultimately, an analysis of AKT phosphorylation on Thr308 and Ser473 (Fig. 4C and D) further validated our findings that single RTK inhibition does not affect the MEK1-mediated feedback loop of activation of the PI3K

Figure 2.
A, heatmap generated from RPPA analysis (mean values from three independent lines) of PI3K–AKT effector proteins from iKRAS cells cultured with doxycycline (KRASG12D expressed), 48 hours after doxycycline withdrawal (KRASG12D ablated), or in the presence of doxycycline after a 48-hour exposure to 2 μmol/L AZD6244. B, representative IHC of AKT–mTOR effector proteins P-GSKα/β, FOXO3a, P6S, and P-4EBP1 in iKRAS-derived allografts. When tumors became palpable mice were maintained with doxycycline (KRASG12D expressed) with or without 100 mg/kg AZD6244 daily treatment or removed from doxycycline (KRASG12D ablated). For immunohistochemical evaluation, tumors were collected 5 days after the beginning of treatment or doxycycline withdrawal. C, time course of AKT phosphorylation levels on residues T308 and S473 in iKRAS cells with continuous KRASG12D expression, after KRASG12D ablation, or in KRASG12D-expressing cells treated with 2 μmol/L AZD6244. D, macroscopic tumor appearance (right) and tumor volumes (left) from iKRAS allografts from mice treated with vehicle, 100 mg/kg every day AZD6244, 40 mg/kg everyday BEZ235, or combined AZD6244 plus BEZ235. Treatments were started when tumors became palpable and continued until excessive tumor burden or ulcerations occurred.
signaling pathway and, conversely, this feedback is abrogated only when coextinction of multiple RTKs is enabled.

Inhibition of multiple RTKs is required to synergize with MEK inhibition and to induce antitumor activity

Because each RTK independently sustains the activity of the PI3K–AKT–MTOR signaling pathway, we sought to evaluate the therapeutic potential of anti-RTK therapy alone or in combination with MEK inhibition. In vitro treatment of iKRAS cells evidenced that none of the RTK inhibitors alone or in combination significantly inhibited growth of iKRAS tumor spheres (Fig. 5A), suggesting that KRASG12D-driven tumors may not require RTK signaling for their growth and survival. Moreover, concomitant treatment of iKRAS cells with AZD6244 and any single RTK inhibitor did not potentiate the activity of AZD6244. Conversely, a robust inhibitory effect was observed when AZD6244 was combined with lapatinib and AXLi, imatinib and AXLi, or even more effectively when AZD6244 was combined with all three RTK inhibitors concurrently (Fig. 5A). To validate these findings in vivo, we treated iKRAS tumor-bearing mice with combinations of AXLi (30 mg/kg/d), imatinib (100 mg/kg/d) or lapatinib (100 mg/kg/d), and AZD6244 (100 mg/kg/d). These experiments confirmed our in vitro findings that coextinction of MEK and of the RTKs activated by MEK inhibition was required to achieve substantial tumor growth inhibition (Fig. 5B).

To address the human relevance of our findings, we treated xenografts derived from a human primary PDAC-harboring mutant KRAS (hereafter named PATC) with vehicle or AZD6244 (100 mg/kg/d) for 5 days and profiled RTK activation status in tumor-derived lysates. MEK inhibition induced a modest increase in P-AXL levels compared with vehicle-treated tumors, and a robust increase of EGFR phosphorylation (Fig. 5C). We then treated cells with lapatinib, AXLi, or their combination alone or in addition to AZD6244 2 μmol/L to determine whether coextinction of multiple RTKs is necessary to induce anti-spherogenic responses. Consistent with previous findings in our murine model of PDAC, only coinhibition of AXL and EGFR along with MEK inhibitor treatment significantly repressed the spherogenic activity of PATC cells (Fig. 5D). These results suggest that inhibiting the RTKs whose activation is induced by MEK inhibition may be required for the development of an MEK inhibitor treatment regimen.

There have been several reports of RTK overexpression in human PDAC tissues (12,24–26), prompting analysis of EGFR, AXL, and PDGFRα levels in a tissue microarray (TMA) containing 136 untreated PDAC cases. All three RTKs were moderately or...
strongly expressed in a significant number of cases (24.2% moderate and 22.8% strong for EGFR, 33.8% moderate and 44.0% strong for AXL and 47.8% moderate and 23.3% strong for PDGFRa; Fig. 5F), supporting the possibility that a relevant fraction of PDAC tumors basally express determinants of resistance to MEK1 inhibition.

Constitutive AKT activation prevents tumor regression upon KRAS\textsuperscript{G12D} ablation

Our data demonstrate that a number of RTKs are upregulated upon MEK inhibition, and that each is able to sustain PI3K–AKT–MTOR activation. To determine whether constitutive activation of PI3K–AKT–MTOR signaling can rescue KRAS\textsuperscript{G12D} dependence, we derived allografts from iKRAS cells transduced with either GFP or a constitutively active myristylated AKT (myr-AKT; Fig. 6A). Both GFP- and myr-AKT–expressing iKRAS cells formed tumors with analogous kinetics, indicating that AKT hyperactivation does not provide an additional growth advantage. However, upon doxycycline withdrawal, GFP-transduced tumors underwent rapid and robust regression, whereas AKT-transduced tumors showed arrested growth but no significant reduction in tumor volume (Fig. 6C). Immunohistochemical analysis of the phosphorylation status of S6 and eIF4E-binding protein 1 (4EBP1) in tumors upon KRAS\textsuperscript{G12D} ablation confirmed the maintenance of pathway activity in myr-AKT–expressing tumors (Fig. 6B). These data demonstrate that AKT activation, although unable to overcome dependency on mutated KRAS for tumor growth, is sufficient to promote tumor maintenance, thereby facilitating eventual escape mechanisms.

Ten to 20% of PDAC tumors carry gain/amplification of AKT2 (27,28), and we hypothesized that this subset of tumors may be insensitive to KRAS\textsuperscript{G12D} ablation. To test this hypothesis, we used MIA PaCa-2 and PANC1 cells, which both harbor mutant KRAS, but only the latter has amplification of 19q13 encompassing the AKT2 locus (29). Both cell lines were transduced with an inducible anti-KRAS shRNA to allow KRAS ablation, and MEK was inhibited with 2 mM AZD6244. In MIA PaCa-2 cells, KRAS knockdown did not increase phospho-AKT levels above the low basal levels observed, in contrast with a marked accumulation of phospho-AKT upon MEK inhibition (analogous to what we previously observed in our murine model; Fig. 6D). Conversely, PANC1 cells presented with basally elevated levels of total AKT and phospho-AKT, neither of which was further increased upon either KRAS knockdown or MEK inhibition, suggesting that, in this cell line, AKT2 amplification drives constitutive activity of the pathway. KRAS knockdown induced apoptosis only in the MIA PaCa-2 cell line (Fig. 6E), supporting the contention that tumors harboring AKT2 amplification are intrinsically independent from mutant KRAS for maintenance.

Figure 4.
A, heatmap generated from RPPA analysis (mean values from three independent lines) of PI3K–AKT effector proteins from iKRAS cells cultured with doxycycline (KRAS\textsuperscript{G12D} expressed) and treated for 48 hours with one or all three RTK inhibitors (RTKi; 1 \(\mu\)mol/L AXLi, 1 \(\mu\)mol/L imatinib, or 1 \(\mu\)mol/L lapatinib) alone or in combination with 2 \(\mu\)mol/L AZD6244. B, representative IHC of phospho-ERK and phospho-S6 of tumors derived from iKRAS allografts treated with AXL 30 mg/kg every day, imatinib 100 mg/kg every day, or lapatinib 200 mg/kg every day, or the combination of each RTK inhibitor with 100 mg/kg every day AZD6244. C, AKT phosphorylation levels on residues T308 and S473 in iKRAS cells cultured in doxycycline (KRAS\textsuperscript{G12D} expressed) and treated for 48 hours with one RTK inhibitor (1 \(\mu\)mol/L AXLi, 1 \(\mu\)mol/L imatinib, or 1 \(\mu\)mol/L lapatinib) alone or in combination with 2 \(\mu\)mol/L AZD6244. D, AKT phosphorylation levels on residues T308 and S473 in iKRAS cells cultured in doxycycline and treated for 48 hours with three RTK inhibitors (RTKi; 1 \(\mu\)mol/L AXLi, 1 \(\mu\)mol/L imatinib, or 1 \(\mu\)mol/L lapatinib) alone or in combination with 2 \(\mu\)mol/L AZD6244. iKRAS cells were also analyzed 48 hours after doxycycline withdrawal (KRAS\textsuperscript{G12D} ablated).
primary PDAC-derived line PATC. Mice received either vehicle or AZD6244 100 mg/kg daily and were sacri-
fical palpable and continued until excessive tumor burden or ulcerations occurred. C, phospho-RTK array of lysates derived from xenografts from the human primary PDAC-derived line PATC. Mice received either vehicle or AZD6244 100 mg/kg daily and were sacrificed 5 days after treatment. D, viability (calcein staining) of PATC cells cultured for 7 days in the presence or absence of 2 μmol/L AZD6244 and treated with either 1 μmol/L AXLi, 1 μmol/L lapatinib, or their combination. E, representative staining of human PDAC strongly positive or negative for AXL. F, number of PDAC cases presenting absent, weak, moderate, and strong staining for either EGFR, AXL, or PDGFRα in a TMA series representative of 136 cases.

Discussion

In contrast with other driver oncogenes such as mutated BRAF or EGFR, effective therapies that directly target mutated KRAS are still unavailable; therefore, attempts to affect KRAS-driven tumors largely depend on an improved understanding of the key effector pathways required for tumor maintenance downstream of KRAS. Unfortunately, clinical studies have shown that abrogation of the MAPK effector pathway alone through MEK inhibitors in KRAS-driven tumors fails to achieve clinical responses (30,31). Accordingly, we failed to see a robust therapeutic response upon MEK inhibition in our murine model of PDAC, whereas ablation of KRASG12D resulted in visibly complete tumor regression, thus underscoring the utility of this model to deeply characterize KRAS effectors. Through comparative analyses of genetic KRASG12D ablation versus MEK inhibition, we identified differentially regulated key effectors. Specifically, in agreement with previous reports (32,33), the sole inhibition of MEK1 promoted the activation of the PI3K pathway whereas KRAS ablation profoundly inhibited both PI3K–AKT–MTOR and MAPK signaling, further emphasizing the need to simultaneously inhibit both pathways to yield a robust antitumor response such as was observed upon KRAS ablation in our iKRAS murine model. Despite numerous previous reports of promising therapeutic efficacy from various combinations of inhibitors of these two pathways (8,9,34), an emerging set of clinical data have shown that these combinations are poorly tolerated, thus limiting their utility (10).

It has been established in multiple tumor models that MEK inhibition engages feedback loops that promote hyperactivation of the PI3K–AKT–MTOR pathway through the recruitment of diverse RTKs, including AXL and PDGFRα (21,22,35). Diverse feedback circuits have been described, including the MTORC1–mediated recruitment of insulin receptor kinase (36,37) and the PI3K–mediated hyperactivation of the ERBB receptors EGFR, HER2, and ERBB3 (21,38). Moreover MEK inhibition–mediated RTK activation was observed in both RAS-mutant and RAS-wt tumor models, indicating that such adaptive response is not unique to mutant RAS-driven tumors (21,22,35). Both of these RTK-mediated feedback loops activate the PI3K pathway, and thereby represent valuable “druggable” therapeutic opportunities that may afford lower toxicity than MEK–PI3K inhibitor combinations. However, although a variety of preclinical studies in diverse tumor models have reported promising antitumor activity by cotargeting of MEK and ERBB receptors (39–41), a recent clinical study of combined therapy with AZD6244 and the anti-EGFR drug erlotinib in patients with chemotherapy-refractory pancreatic cancer reported that antitumor activity was only achieved in a subset of patients (42).

We profiled RTK activation and therapeutic responses to targeting the RTK-mediated feedback loops in our murine model. Surprisingly, we observed that RTK activation occurs both upon KRASG12D ablation and MEK inhibition, although in the former this event fails to induce AKT hyperactivation or to promote tumor maintenance, suggesting that continuous KRASG12D signaling is required to promote RTK-mediated activation of the PI3K pathway. Importantly, the RTK activation we observed included not only HER1–2, but also the TAM receptor AXL as well as PDGFRα. Moreover, the mechanism of activation of AXL and PDGFRα involves both upregulation of the RTK itself as well
as transcriptional upregulation of their ligands, suggesting that, upon MEK inhibition, tumor cells possess the ability to engage autonomous regulatory circuits rather than relying solely on the supply of growth factors from the microenvironment.

To evaluate the contribution of each RTK activated upon MEK inhibitor treatment, we tested whether inhibition of any one RTK exerted dominant control over prosurvival pathway activation, which may help elucidate strategies for targeted therapy combinations. These efforts included extensive characterization of a novel AXL inhibitor with unprecedented selectivity and potency compared with all others previously described. We showed that inhibition of any single RTK activated by MEK inhibitor treatment did not yield antitumor efficacy above that achieved with the MEK inhibitor alone. Rather, concomitant inhibition of all of the diverse RTKs activated upon MEK inhibition was required to yield synergistic effects with MEK inhibition in both our iKRAS murine model, as well as in an MEK inhibitor–treated model derived from human primary PDAC. This result has profound clinical relevance, as it underscores the need for personalized therapy combinations based on a rational coextinction strategy versus blind enrollment into trials that combine an MEK inhibitor with a single RTK inhibitor. Moreover, consistent with previous reports, we found detectable AXL and PDGFRa expression in a number of human PDAC samples (24–26), suggesting that many patients present with tumors that may be easily resistant to MEK–HER inhibitor combinations. Furthermore, our data are in line with previous evidence that activation of AXL and PDGFRa can drive resistance to anti-EGFR treatment (43,44) and, in the case of AXL, to anti-MEK1 therapy (45,46). Proteomic profiling of iKRAS cells upon MEK inhibition and treatment with single or multiple RTK inhibitors showed that each RTK can independently sustain hyperactivity of the PI3K pathway mediated by MEK inhibition.

Given the striking dominance of the PI3K signaling pathway activation in tumor maintenance, we asked whether a fraction of PDAC-harboring genomic aberrations driving constitutive activation of this pathway such as AKT2 amplification, which occurs in 10% to 20% of PDACs (27,28), may render this subset of patients insensitive not only to MEK–RTK inhibitors, but also to continuous KRAS signaling. Indeed, constitutive activation of the PI3K–AKT pathway prevented tumor regression upon KRAS ablation and, furthermore, cell lines harboring AKT2 amplification manifested resistance not only to MEK inhibition, but also to genetic abrogation of KRAS.

Collectively, our findings suggest that combinatorial MEK–RTK-targeted therapies may have limited impact without careful patients stratification to therapy combinations based on an individual’s oncogene and on the activation state of signal transduction pathways at time of treatment. On the basis of this, a personalized therapy strategy that accounts for the genomic aberrations driving constitutive activity of the PI3K signaling pathway, as well as a deep analysis of feedback circuits engaged by MEK inhibition, is more likely to result in positive clinical outcomes than random assignment to combination therapies to inhibit MEK and a single RTK. An improved and comprehensive understanding of these and additional mechanisms that allow survival of tumors cells despite suppression of mutant KRAS-mediated signaling (16,47) will define possibly definitive therapeutic strategies.
Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Authors’ Contributions
Conception and design: P. Pettazzoni, A. Viale, A. Carugo, T.P. Hefferman, P. Jones, G.F. Draetta
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): P. Pettazzoni, A. Viale, A. Carugo, H. Ying, H. Wang, E. Huang-Hobbs, N. Sanchez, W. Yao, J.B. Fleming
Writing, review, and/or revision of the manuscript: P. Pettazzoni, A. Viale, P. Shah, N. Sanchez, A.K. Deem, G.B. Mills, T.P. Hefferman, C. Toniatti, R.A. DePinho, G.F. Draetta
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): A. Viale, R. Minelli, T. Green, M. Marchesini, M.E. Di Francesco, K. Scott, G.B. Mills
Study supervision: T.P. Hefferman, C. Toniatti, G.F. Draetta

References

Other (provided chemical compound for experiment): A. Petrocchi
Other (provided reagents): S. Colla

Acknowledgments
The authors thank Shan Jiang for her expert management of the mouse colony and Dr. Lynda Chin for helpful suggestions. Alessandro Carugo is a PhD student at the Department of Experimental Oncology, European Institute of Oncology, Italy.

Grant Support
This study was supported by grants from the Hirshberg Foundation for Pancreatic Cancer Research (A. Viale), Sheikh Ahmed Center for Pancreatic Cancer Research (G.F. Draetta, T.P. Hefferman, and A. Viale), the American Italian Cancer Foundation (G.F. Draetta), D01CA117969 (R.A. DePinho), and RPPA was supported by CCSG grant P30 CA016672 and by an Italian American Cancer Foundation Post-Doctoral Research Fellowship (P. Pettazzoni).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received June 23, 2014; revised October 21, 2014; accepted November 9, 2014, published OnlineFirst March 3, 2015.

Downloaded from cancerres.aacrjournals.org on April 30, 2017. © 2015 American Association for Cancer Research.
Multiple RTKs and AKT2 Amplification Limit Anti-MEK1 Efficacy in Pancreas Cancer


Genetic Events That Limit the Efficacy of MEK and RTK Inhibitor Therapies in a Mouse Model of KRAS-Driven Pancreatic Cancer

Piergiorgio Pettazzoni, Andrea Viale, Parantu Shah, et al.


<table>
<thead>
<tr>
<th>Updated version</th>
<th>Access the most recent version of this article at: doi:10.1158/0008-5472.CAN-14-1854</th>
</tr>
</thead>
<tbody>
<tr>
<td>Supplementary Material</td>
<td>Access the most recent supplemental material at: <a href="http://cancerres.aacrjournals.org/content/suppl/2015/04/04/0008-5472.CAN-14-1854.DC2">http://cancerres.aacrjournals.org/content/suppl/2015/04/04/0008-5472.CAN-14-1854.DC2</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Cited articles</th>
<th>This article cites 46 articles, 21 of which you can access for free at: <a href="http://cancerres.aacrjournals.org/content/75/6/1091.full.html#ref-list-1">http://cancerres.aacrjournals.org/content/75/6/1091.full.html#ref-list-1</a></th>
</tr>
</thead>
<tbody>
<tr>
<td>Citing articles</td>
<td>This article has been cited by 4 HighWire-hosted articles. Access the articles at: <a href="/content/75/6/1091.full.html#related-urls">/content/75/6/1091.full.html#related-urls</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>E-mail alerts</th>
<th>Sign up to receive free email-alerts related to this article or journal.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reprints and Subscriptions</td>
<td>To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at <a href="mailto:pubs@aacr.org">pubs@aacr.org</a>.</td>
</tr>
<tr>
<td>Permissions</td>
<td>To request permission to re-use all or part of this article, contact the AACR Publications Department at <a href="mailto:permissions@aacr.org">permissions@aacr.org</a>.</td>
</tr>
</tbody>
</table>